Screening for diabetic retinopathy

New England Journal of Medicine

Volumn 376, Issue 16, 2017, Pages 1587-1588

  Rosenberg, Jamie B ^a   Tsui, Irena ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYDROXYCHLOROQUINE; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

BLOOD PRESSURE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DISEASE DURATION; EDITORIAL; ENDOCRINOLOGIST; EYE EXAMINATION; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HEALTH CARE SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOW RISK POPULATION; MACULAR DEGENERATION; MACULAR EDEMA; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; OPHTHALMOLOGIST; PATIENT REFERRAL; RETINOPATHY; RETROLENTAL FIBROPLASIA; RISK ASSESSMENT; SCREENING TEST; WEIGHT GAIN; MASS SCREENING;

DIABETIC RETINOPATHY; HUMANS; MASS SCREENING; REFERRAL AND CONSULTATION;

EID: 85018510696     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1701820     Document Type: Editorial

References (10)

1. The DCCT/EDIC Research Group. Frequency of evidencebased screening for retinopathy in type 1 diabetes. N Engl J Med 2017; 376: 1507-16
2. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016; 123: 1386-94
3. Gurwin J, Tomlinson LA, Quinn GE, et al. A tiered approach to retinopathy of prematurity screening (TARP) using a weight gain predictive model and a telemedicine system. JAMA Ophthalmol 2017 January 5 (Epub ahead of print)
4. Taylor-Phillips S, Mistry H, Leslie R, et al. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review. Br J Ophthalmol 2016; 100: 105-14
5. Aspelund T, Thornórisdóttir O, Olafsdottir E, et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 2011; 54: 2525-32
6. Javitt JC, Aiello LP, Chiang Y, Ferris FL III, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health-care reform. Diabetes Care 1994; 17: 909-17
7. Schoenfeld ER, Greene JM, Wu SY, Leske MC. Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. Ophthalmology 2001; 108: 563-71
8. Kraft SK, Marrero DG, Lazaridis EN, Fineberg N, Qiu C, Clark CM Jr Primary care physicians' practice patterns and diabetic retinopathy: current levels of care. Arch Fam Med 1997; 6: 29-37
9. Rosenberg JB, Friedman IB, Gurland JE. Compliance with screening guidelines for diabetic retinopathy in a large academic children's hospital in the Bronx. J Diabetes Complications 2011; 25: 222-6
10. Levin AM, Rusu I, Orlin A, et al. Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections. Clin Ophthalmol 2017; 11: 193-200